Guggenheim initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Reports Q3 2025 Financial Results
- Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
- Foghorn Therapeutics CFO Kristian Humer Resigns
- Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
- Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating